Cytori Approved to Initiate Pivotal Stem & Regenerative Cell Heart Attack Trial in Europe; First ADVANCE Trial Site to Begin Enrollment in the Netherlands - Seite 2

generation devices (based on Cytori´s existing Celution® System) that will
process and concentrate adult stem and regenerative cells residing in adipose
tissue. The alliance creates valuable synergies between two companies that share
the same vision for regenerative medicine. Olympus, as a leader in the
development of innovative medical products, contributes its expertise in
engineering, manufacturing, and quality assurance of sophisticated devices.
Cytori´s focus is dedicated to the development and commercialization of
therapeutic applications using adipose stem and regenerative cells in multiple
large medical markets. Olympus-Cytori is establishing the premier brand of
point-of-care cell therapy devices in the emerging field of regenerative
medicine.

Cytori´s Cautionary Statements

This press release includes forward-looking statements regarding future events
and expectations, including but not limited to Cytori´s ability to gain the
necessary additional trial-center approvals for the Advance trial, and the
ability of the Celution One system to perform in accordance with its
specifications within the Advance trial. These forward looking statements
involve risks and uncertainties, including the Company´s ability to satisfy the
requirements of various local regulatory authorities, the Company´s ability to
manage a large multi-center, multi-regional complex clinical trial, and the
capability of the Celution One device to perform successfully in the clinical
setting, as well as other factors which may be beyond the Company´s control. For
additional disclosure regarding these and other risks faced by Cytori
Therapeutics, we refer the reader to carefully review the section titled "Risk
Factors" in Cytori´s filings with the SEC, including its annual report on Form
10-K for the year ended December 31, 2009 and subsequent quarterly reports on
Form 10-Q. Cytori assumes no responsibility to update any forward-looking
statements contained in this press release to reflect events, trends or
circumstances after the date of this press release.

The Celution One System - the next generation of the Celution device,
manufactured by Olympus-Cytori:
http://media.marketwire.com/attachments/201101/MOD-25255_Celution_ONE.jpg

Contacts
Megan McCormick
858.875.5279
[e-mail]

College Hill
Adam Michael/Gemma Howe
[phone]
[e-mail]

This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.

Source: Cytori Therapeutics, Inc. via Thomson Reuters ONE

[HUG#1481108]

Wertpapiere des Artikels:
US23283K1051